# Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma

> **NCT03364530** · PHASE2 · RECRUITING · sponsor: **University Hospital, Montpellier** · enrollment: 40 (estimated)

## Conditions studied

- Cholangiocarcinoma Non-resectable
- Non-metastatic

## Interventions

- **DRUG:** Gemcitabine-Oxaliplatin Regimen
- **PROCEDURE:** Hepatic intra arterial chemotherapy

## Key facts

- **NCT ID:** NCT03364530
- **Lead sponsor:** University Hospital, Montpellier
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-06-11
- **Primary completion:** 2025-10-21
- **Final completion:** 2026-10-21
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-01-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03364530

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03364530, "Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03364530. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*